NCT00113399 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Radiation Therapy on weeks 1, 3, 5, and 7; 1.5 Gy/fx, twice daily x 5 days, 40 fractions, for a total dose of 60 Gy; Chemotherapy (cisplatin/paclitaxel) on weeks 1, 3, 5, and 7 G-CSF on weeks 2, 4, 6, and 8. \[Data is reported for eligible patients with adverse event information, which is 6 patients.\]
- id
- FG000
- title
- Re-irradiation Plus Concurrent Chemotherapy
- description
- Select from one of the three standard chemotherapy regimens: cisplatin/5-FU; cisplatin/paclitaxel; cisplatin/docetaxel. \[Data is reported for eligible patients with adverse event information, which is 7 patients.\]
- id
- FG001
- title
- Chemotherapy Alone
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Complete Response
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Other
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 8
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 3
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 5
- type
- NOT COMPLETED
- title
- Overall Study
Complete source fields
- groups
- description
- Radiation Therapy on weeks 1, 3, 5, and 7; 1.5 Gy/fx, twice daily x 5 days, 40 fractions, for a total dose of 60 Gy; Chemotherapy (cisplatin/paclitaxel) on weeks 1, 3, 5, and 7 G-CSF on weeks 2, 4, 6, and 8. \[Data is reported for eligible patients with adverse event information, which is 6 patients.\]
- id
- FG000
- title
- Re-irradiation Plus Concurrent Chemotherapy
- description
- Select from one of the three standard chemotherapy regimens: cisplatin/5-FU; cisplatin/paclitaxel; cisplatin/docetaxel. \[Data is reported for eligible patients with adverse event information, which is 7 patients.\]
- id
- FG001
- title
- Chemotherapy Alone
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 1
- group Id
- FG001
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Complete Response
- reasons
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 1
- type
- Other
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 7
- group Id
- FG001
- num Subjects
- 8
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 5
- group Id
- FG001
- num Subjects
- 3
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 2
- group Id
- FG001
- num Subjects
- 5
- type
- NOT COMPLETED
- title
- Overall Study
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle